2013 - 2021
Identification of new drug targets in CML and other MPN.
The project part leader, Giulio Superti-Furga, is Director of CeMM (Vienna, Austria) and well-known and well-embedded in the scientific community. His group conducted pioneering research in the structural analysis of BCR/ABL and in the characterization of major BCR/ABL-drug interactions. In addition, his group established kinase interaction profiles for various TKI in CML. The lab of the PI worked on three converging tracks, with the aims to perform structure-function analyses of BCR/ABL to identify new critical target-sites, to characterize the molecular machinery and wider protein interaction networks that integrate BCR/ABL within the CML cell signaling pathways and biological processes, and to use chemical proteomics to elucidate the mechanism-of-action and target spectra of various TKI.